ProMIS Neurosciences, based in Toronto, develops precision medicine for neurodegenerative diseases, focusing on antibody therapeutics targeting misfolded proteins. The company went public on April 3, 2017, and employs six full-time staff.
ProMIS Neurosciences (PMN) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, ProMIS Neurosciences's actual EPS was -$0.21, missing the estimate of -$0.12 per share, resulting in a -73.27% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
